B. Metzler seel. Sohn & Co. AG Sells 512,513 Shares of Abbott Laboratories $ABT

Key Points

• B. Metzler seel. Sohn & Co. AG cut its Abbott Laboratories stake by 28.1%, selling 512,513 shares during the second quarter. It still held 1.31 million shares worth approximately $119 million.
• Abbott reported quarterly EPS of $1.31, topping estimates by $0.03, while revenue rose 13% year over year to $12.59 billion. The company guided for full-year 2026 EPS of $5.45–$5.60.
• Abbott declared a quarterly dividend of $0.63, equivalent to an annualized $2.52 payout and a 2.3% yield. Analysts maintain a “Moderate Buy” consensus with an average price target of $119.50.

B. Metzler seel. Sohn & Co. AG decreased its stake in Abbott Laboratories (NYSE:ABT - Free Report) by 28.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,311,875 shares of the healthcare product maker's stock after selling 512,513 shares during the period. Abbott Laboratories comprises about 1.0% of B. Metzler seel. Sohn & Co. AG's investment portfolio, making the stock its 21st biggest position. B. Metzler seel. Sohn & Co. AG owned 0.08% of Abbott Laboratories worth $119,039,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. MidAtlantic Capital Management Inc. bought a new stake in Abbott Laboratories during the fourth quarter worth about $25,000. Cornerstone Financial Management LLC purchased a new position in Abbott Laboratories during the 4th quarter valued at about $25,000. Purpose Unlimited Inc. bought a new position in shares of Abbott Laboratories during the fourth quarter valued at approximately $25,000. Portfolio Resources Advisor Group Inc. purchased a new stake in shares of Abbott Laboratories in the 4th quarter worth about $26,000. Finally, Abound Financial LLC bought a new stake in Abbott Laboratories during the 4th quarter valued at approximately $26,000. 75.18% of the stock is owned by institutional investors.

Abbott Laboratories Price Performance

NYSE ABT opened at $108.29 on Friday. Abbott Laboratories has a one year low of $81.97 and a one year high of $137.49. The stock has a 50-day moving average of $104.43 and a 200 day moving average of $100.12. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. The company has a market capitalization of $187.38 billion, a price-to-earnings ratio of 35.05, a PEG ratio of 2.01 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The firm had revenue of $12.59 billion for the quarter, compared to the consensus estimate of $12.52 billion. During the same quarter last year, the firm posted $1.26 EPS. The business's quarterly revenue was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, sell-side analysts forecast that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th were given a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend was Wednesday, July 15th. Abbott Laboratories's payout ratio is 81.55%.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on ABT shares. The Goldman Sachs Group reduced their target price on shares of Abbott Laboratories from $121.00 to $113.00 and set a "buy" rating on the stock in a research report on Wednesday, May 27th. Wells Fargo & Company boosted their price target on Abbott Laboratories from $109.00 to $112.00 and gave the stock an "overweight" rating in a research report on Friday, July 17th. Citigroup raised their price objective on Abbott Laboratories from $108.00 to $112.00 and gave the company a "buy" rating in a research report on Friday, July 17th. Robert W. Baird initiated coverage on Abbott Laboratories in a research note on Wednesday, July 1st. They set an "outperform" rating and a $121.00 price objective for the company. Finally, TD Cowen increased their price objective on shares of Abbott Laboratories from $115.00 to $135.00 and gave the company a "buy" rating in a research report on Tuesday, August 25th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, Abbott Laboratories currently has a consensus rating of "Moderate Buy" and an average target price of $119.50.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.